More than 80 companies currently claim to offer manufacturing related services / By Roots Analysis

Several big pharma companies are known to outsource more than half of their clinical-stage oligonucleotide manufacturing operations. Anticipating a sharp rise in demand, oligonucleotide manufacturers are increasingly consolidating their portfolios, building new capabilities and expanding their respective capacities, mostly through acquisitions, in order to gain a competitive edge.

To order this 300+ page report, which features 140+ figures and 190+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/oligonucleotide-synthesis/304.html

Key Inclusions

• A detailed review of the current status of the market with respect to oligonucleotide manufacturers focused on research and diagnostic, and therapeutic applications. It features information on the year of establishment, company size, scale of operation (preclinical, clinical, and commercial), location of headquarters, number of manufacturing facilities, along with their locations (country-wise), and regulatory accreditations and certifications received by them, type of oligonucleotide manufactured (antisense oligonucleotides, aptamers, decoys, miRNA, shRNA, siRNA, specialty amidites, and others), type of offering (custom synthesis, modification and purification), type of manufacturing service(s) offered (process development and characterization, method validation and testing, analytical development, sequencing capabilities, stability studies, quality assurance and control, scale-up, fill/finish, downstream processing, regulatory support, data analytics and reporting, and others), type of modification(s) offered (amino modifiers, backbone modifications, fluorescent probes, dyes and quenchers, modified bases, phosphorylation, thiol modifications, and others), type of purification method(s) used (desalting, cartridge purification, HPLC, ion exchange purification, PAGE, and others), and compliance to cGMP standards.
• A company competitiveness analysis, highlighting prominent oligonucleotide manufacturers for research and diagnostic, and therapeutic applications, based on supplier strength (which was calculated by considering the size of employee base of a company and its experience in this field) and service strength (quantified based on scale of operation, expertise in manufacturing different types of oligonucleotides, type of offering, type of manufacturing service(s) offered, type of modification(s) offered, type of purification method(s) used, compliance to cGMP standards, as well as number and location of manufacturing facilities).
• Elaborate profiles of key players that offer a diverse range of capabilities for custom synthesis, modification and purification of oligonucleotides for use in research and diagnostic, and therapeutic applications. Each profile includes an overview of the company, its financial performance (if available), information related to its service portfolio, manufacturing facilities, details on partnerships, recent developments (expansions), and awards received by the firm, as well as an informed future outlook.

The USD 5.8 billion (by 2030) financial opportunity within the oligonucleotide synthesis, modification and purification services market has been analyzed across the following segments:

• Type of manufacturing
• Custom manufacturing
• Large-scale manufacturing

• Type of Oligonucleotides manufactured
• Antisense Oligonucleotides
• miRNAs
• shRNAs
• siRNAs
• Other Oligonucleotides

• Scale of operation
• Clinical
• Commercial

• Purpose of production
• In-house
• Outsourced

• Target therapeutic area
• Autoimmune Disorders
• Cardiovascular Disorders
• Genetic Disorders
• Infectious Diseases
• Metabolic Disorders
• Neuromuscular Disorders
• Oncological Disorders
• Ophthalmic Disorders
• Other Therapeutic Areas

• Size of manufacturer
• Small
• Mid-sized
• Large

• Key Geographical Region
• North America
• Europe
• Asia-Pacific and Rest of the World

The Oligonucleotide Synthesis, Modification and Purification Services Market: Focus on Research, Diagnostic and Therapeutic Applications, 2020-2030”report features the following companies, which we identified to be key players in this domain:

• Agilent Technologies
• Ajinomoto Bio-Pharma Services
• BioSpring
• CordenPharma
• Integrated DNA Technologies
• Kaneka Eurogentec
• LGC Biosearch Technologies
• Microsynth
• Nitto Denko Avecia
• Sigma Aldrich
• Thermo Fisher Scientific
• Trilink Biotechnologies

Table of Contents

1. Preface

2. Executive Summary

3. Introduction
 

4. Market Landscape: Oligonucleotide Manufacturers (Research and Diagnostic Applications)
 

5. Market Landscape: Oligonucleotide Manufacturers (Therapeutic Applications)
 

6. Company Competitiveness Analysis: Oligonucleotide Manufacturers (Research and Diagnostic Applications)
 

7. Company Competitiveness Analysis: Oligonucleotide Manufacturers (Therapeutic Applications)
 

8. Company Profiles: Oligonucleotide Manufacturers (Research and Diagnostic Applications)
 

9. Company Profiles: Oligonucleotide Manufacturers (Therapeutic Applications)
 

10. Partnerships and Collaborations
 

11. Recent Expansions
 

12. Clinical Trial Analysis

13. Capacity Analysis

14. Demand Analysis
 

15. Market Sizing and Opportunity Analysis

16. Swot Analysis
 

17. Survey Analysis

18. Executive Insights

19. Concluding Remarks

20. Appendix 1: Tabulated Data

21. Appendix 2: List of Companies and Organizations

To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/oligonucleotide-synthesis/304.html

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

[email protected]